A clinical study on the treatment of generalized anxiety disorder with the

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000040651

Enrollment

Unknown

Registered

2020-12-06

Start date

2020-12-10

Completion date

Unknown

Last updated

2021-03-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Generalized anxiety disorder

Interventions

The control group:Paroxetine hydrochloride is taken orally

Experimental group:Sancai acupuncture combined with oral paroxetine hydrochloride

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. MEET the diagnostic criteria of GAD in CCMD-3; 2. The age should be 18-75 years old; 3. Hamilton Anxiety Scale (HAMA) score >=14; 4. Patients who receive and adhere to western medicine or acupuncture treatment; 5. Sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. Secondary anxiety of somatic diseases, drug withdrawal reaction, and secondary anxiety of other mental diseases; 2. Pregnant and lactating women with severe cardiopulmonary, liver and kidney dysfunction; 3. History of organic brain disease and serious mental illness; 4. Those who are receiving systematic psychological treatment; 5. Those who have failed to respond to previous treatment with paroxetine or are allergic; 6. There is inflammation, scar or trauma at the site of operation, or other severe systemic infection.

Design outcomes

Primary

Measure	Time frame
HAMA Evaluation Questionnaire;HAMA Evaluation Questionnaire;Whoqol-bref Evaluation Questionnaire;	—

Countries

China

Contacts

Public ContactJianQIN Lv

West China Hospital, Sichuan University

372651647@q.com+86 13880697657

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026